Cytarabine

Catalog No.S1648

Cytarabine Chemical Structure

Molecular Weight(MW): 243.22

Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

Size Price Stock Quantity  
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 12 Publications

3 Customer Reviews

  • Viability and CI vs Fa after 24-h exposure to cytarabine alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM (500 ng/ml for cytarabine; quadruplicates±s.e.m.).

    Leukemia, 2015, 29(8): 1702–1712. Cytarabine purchased from Selleck.

    Cell cycle was analyzed using propidium iodide (PI) staining and flow cytometry. The plots show PI staining at the x-axis and cell counts at the y-axis. The graphs were prepared using ModFit LT™ software (Verity Software House). Nd: not detected, Ara-c:Cytarabine

    J Exp Clin Cancer Res, 2017, 36(1):22. Cytarabine purchased from Selleck.

  • Flow cytometry analysis for cell surface expression of CD11b shows time- and dose-dependent upregulation of the marker CD11b in MLL-rearranged leukemia cells treated with EPZ-5676 and Cytarabine(Ara-C) as single agents and in combination.

    J Pharmacol Exp Ther, 2014, 350(3): 646-56. Cytarabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.
Features The 1st of a series of cancer drugs that alters the sugar component of nucleosides.
Targets
DNA synthesis [1]
(CCRF-CEM cells)
16 nM
In vitro

Cytarabine (AraC) is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM. [1] Increasing concentrations of Cytarabine (IC50 of 0.69 μM) results in decreased metabolic activity of sensitive rat leukemic cell line RO/1, and the cell toxity can be highly enhanced by transfection with human wt dCK (IC50 of 0.037 μM) but not the inactive, alternatively spliced dCK forms. [2] Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse L1210 cells MYHDfZRwfG:6aXRCpIF{e2G7 NGmyR44{KGSjeYO= MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBl\W:6eX71Z4xmd3OrZHWgZY5idG:pdXWtd4Vve2m2aY\lJI1wfXOnIFyxNlExKGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;MD60JI5ONg>? NX[ybJNwOTl4N{S5NFM>
human CCRF-CEM cells MVzDfZRwfG:6aXRCpIF{e2G7 MY[zJIRigXN? NYjjUFN4S3m2b4TvfIlkcXS7IHHnZYlve3RiZHXvfJlvfWOuZX;zbYRmKGGwYXzv[5VmNXOnboPpeIl3\SCqdX3hckBES1KILVPFUUBk\WyuczDh[pRmeiB|IHThfZMh[nliTWTUJIF{e2G7LDDJR|UxRTFibl2u M4XmV|E6Pjd2OUCz
human MCF7 cells NFPab2tEgXSxdH;4bYPDqGG|c3H5 MUGzJIRigXN? M1PleGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGSnb4j5cpVkdGWxc3nk[UBidmGub3f1[U1{\W6|aYTpeoUhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGG|c3H5MEBKSzVyPUSgcm0v MVKxPVY4PDlyMx?=
CCRF-CEM cell line NHrvTm1HfW6ldHnvckBie3OjeR?= MVjJcohq[mm2IITo[UBz\XCuaXPheIlwdiCxZjDDR3JHNUOHTTDj[YxtKGyrbnWgbY4hfmm2cn:sJGVFPTB;NTDuUU4> MkXHNVk6PTh7NB?=
human P12-ICHIKAWA cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M17QVWlvcGmkaYTpc44hd2ZiaIXtZY4hWDF{LVnDTGlMSVeDIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT61OEBvVS5? NW[5S25tW0GQR1XS
human CCRF-CEM cells Ml7aR5l1d3SxeHnjxsBie3OjeR?= MYG0PEBp NWjHdmFuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0OURj3DSW0h[2WubIOgZYZ1\XJiNEigbJJ{KGK7IHPlcIwhfGm2ZYKtZox2\SCjc4PhfUwhTUN3ME21MlYyKG6PLh?= NFPSXJkyQTd2M{i1PC=>
CCRF-CEM cell lines MoDJSpVv[3Srb36gZZN{[Xl? NIS4SG04OiCq NYS4bmVlS2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JJJmeGyrY3H0bY9vKG:oIFPDVmYuS0WPIHPlcIwhdGmwZYOgZpkhPTBnIHHmeIVzKDd{IHjyJIlv[3WkYYTpc44tKEWGNUC9OkBvVS5? MUCxOlUzODJ2
human CCRF-CEM cells NWTOPIV6S3m2b4TvfIlkyqCjc4PhfS=> MmDyOFghcA>? NWTGcYsyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0OURj3DSW0h[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IHPlcIx1cXSncj3icJVmKGG|c3H5MEBKSzVyPU[gcm0v M4fUcFIzPTh{OUmx
human SF268 cells NHPNTGFEgXSxdH;4bYPDqGG|c3H5 NUDNUpViS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUeuOlghdk1w MXixPVM1PTV6MR?=
MOLT-4 human leukemic lymphoblastoid cell lines M2Xke2N6fG:2b4jpZ:Kh[XO|YYm= NXfKeHlXS3m2b4TvfIlkcXS7IHHnZYlve3RiTV;MWE01KGi3bXHuJIxmfWunbXnjJIx6dXCqb3LsZZN1d2mmIHPlcIwhdGmwZYOsJGlEPTB;MUCgcm0v MlL0OlgzPzV2Nh?=
human 697 cell M2TiWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn\XTY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMD62JI5ONg>? MWnTRW5ITVJ?
human ES1 cell NFvkTplIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MULJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF{Lkm3JI5ONg>? MofvV2FPT0WU
CCRF-CEM human leukemic lymphoblastoid cell lines MnTBR5l1d3SxeHnjxsBie3OjeR?= NEPJeoFEgXSxdH;4bYNqfHliYXfhbY5{fCCFQ2LGMWNGVSCqdX3hckBt\XWtZX3pZ{BtgW2yaH;icIF{fG:rZDDj[YxtKGyrbnXzMEBKSzVyPUKwJI5ONg>? NWS2c2JqPjh{N{W0Oi=>
P388 murine cell lines MVrGeY5kfGmxbjDhd5NigQ>? NGLYV5o4OiCq MYPUbIUh[2:vcH;1coQhf2G|IITld5Rm\CCrbjD2bZRzdyCob4KgZY51cXS3bX;yJIFkfGm4aYT5LFUxLSCrbnjpZol1cW:wIH;mJJR2dW:{IHPlcIwh\3Kxd4ToLUBi\2GrboP0JJRp\SCSM{i4JI12emmwZTDj[YxtKGyrbnXzJIFnfGW{IEeyJIhwfXK|LDDJSFUxRTJyIH7NMi=> MlPqN|YzPTdzNB?=
L1210 murine cell lines MYDGeY5kfGmxbjDhd5NigQ>? M3vQUlczKGh? Mki4WIhmKGOxbYDveY5lKHejczD0[ZN1\WRiaX6geol1em9iZn;yJIFvfGm2dX3vdkBi[3Srdnn0fUg2OCViaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEkh[WejaX7zeEB1cGViTEGyNVAhdXW{aX7lJINmdGxibHnu[ZMh[W[2ZYKgO|IhcG:3coOsJGlFPTB;MkCgcm0v M4DwOlM3OjV5MUS=
human HEL cell MmnoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYrxUlltUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNE42OiCwTT6= NVPUPHQ2W0GQR1XS
human CCRF-CEM/C2 cells MXPDfZRwfG:6aXRCpIF{e2G7 MlXBOFghcA>? MmXER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2NTTi2FRV2vR|Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IHPlcIwhfGm2ZYKtZox2\SCjc4PhfUwhTUN3ME2yNk45KG6PLh?= NWTUeYNDOTl5NEO4OVg>
mouse L1210 cells M2TiemN6fG:2b4jpZ:Kh[XO|YYm= MnHKOFghcA>? MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDMNVIyOCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC0PEBpenNuIFnDOVA:OC5yMkSg{txONg>? NXvw[2toOjByMEC0NVg>
human CEM cells MX\DfZRwfG:6aXRCpIF{e2G7 NYjKOpl{PDhiaB?= MlvkR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VOKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IES4JIhzeyxiSVO1NF0xNjB{NDFOwG0v MoX5NlAxODB2MUi=
human 2209-23 cells NX36VHRLWHKxbHnm[ZJifGmxbjDhd5NigQ>? NG\JR2lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEKyNFkuOjNiY3XscJMh[nliW{PIYZRpgW2rZHnu[UBqdmOxcoDvdoF1cW:wIIPjbY51cWyuYYTpc44heHKxeHntbZR6KGG|c3H5MEBKSzVyPUCuNFI6KM7:TR?= NWjFS4F3OTlyNUW0PFI>
human CHP-212 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUG5XJNyUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzNwNEegcm0v M3XIT3NCVkeHUh?=
human CTB-1 cell NFPiWmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoX2TY5pcWKrdHnvckBw\iCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO0MlMhdk1? MmPtV2FPT0WU
human A427 cell M3zkWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWXJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|ND60PUBvVS5? MlX4V2FPT0WU
human MOLT-16 cell M2G4XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NITrXW5KdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Pi5yNzDuUU4> MoC5V2FPT0WU
human MCF7 1K cells NYrIWHFqS3m2b4TvfIlkyqCjc4PhfS=> NIjEeo8{KGSjeYO= MnixR5l1d3SxeHnjbZR6KGGpYXnud5Qh\GWxeInueYNt\W:|aXTlJIFv[WyxZ4XlMZJme2m|dHHueEBpfW2jbjDNR2Y4KDGNIHPlcIx{KG:4ZYLlfJBz\XO|aX7nJJJq[m:wdXPs[Y91cWSnIILl[JVkfGG|ZTDh[pRmeiB|IHThfZMh[nliTWTUJIF{e2G7LDDJR|UxRTRyIH7NMi=> NUj0NWNzOTl4N{S5NFM>
human MC-IXC cell M4\TUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3jmemlvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFEvPDFibl2u MYfTRW5ITVJ?
human BHT-101 cell MnPVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEDTZYZKdmirYnn0bY9vKG:oIHj1cYFvKEKKVD2xNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01OS55NjDuUS=> MVrTRW5ITVJ?
human K5 cell NYHGWFJUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PDNwMjDuUS=> NI\JUXhUSU6JRWK=
parent promyelocytic leukemia cell line MWjGeY5kfGmxbjDhd5NigQ>? NInkSFZCdnSrY3HuZ4VzKGGldHn2bZR6KHejczDleoFtfWG2ZXSg[o9zKHSqZTDjc41xd3WwZDDh[4FqdnO2IIDhdoVvfCCycn;tfYVtd2O7dHnjJIxmfWunbXnhJINmdGxibHnu[UApUExvNkCtS2hRWlRtL3TDT{sqNCCHREWwQVQ4KG6PLh?= MUizNFI4OzJ7
human HL60 cells MmrDR5l1d3SxeHnjxsBie3OjeR?= NHTOW3hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDZyIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBk\WyudHn0[ZIu[my3ZTDhd5NigSxiSVO1NF0xNjB2OTFOwG0v MVuyNlU5Ojl7MR?=
human A549 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12OT62OkBvVQ>? M1XsS3NCVkeHUh?=
human NCI-H1703 cell NVnRc2dKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHXqU2tKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVcxOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR7LkixJI5O M1vybnNCVkeHUh?=
L1210 cell lines MnfQSpVv[3Srb36gZZN{[Xl? MX\Dc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRicnXwcIlk[XSrb36gc4YhVDF{MUCgZ4VtdCCuaX7ld{BjgSB3MDWgZYZ1\XJiN{KgbJIhcW6ldXLheIlwdixiRVS1NF0xNjB3IN88UU4> MoDNNVY2OjB{NB?=
human K562 cells MkjXR5l1d3SxeHnjxsBie3OjeR?= MkDkR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT|U3OiClZXzsd{BjgSCVUlKgZZN{[XluIFnDOVA:OC5yNTFOwG0> MmfONlQ6PTZ3NU[=
human LB2241-RCC cell NEHqe|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV\PWmdjUW6qaXLpeIlwdiCxZjDoeY1idiCOQkKyOFEuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUWuN|Qhdk1? MVLTRW5ITVJ?
human MLMA cell NH;jd4hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEHyXFhKdmirYnn0bY9vKG:oIHj1cYFvKE2OTVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21OU42OSCwTR?= M4ixT3NCVkeHUh?=
human P30-OHK cell NHzIN3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHe2NZpKdmirYnn0bY9vKG:oIHj1cYFvKFB|MD3PTGsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Pi53IH7N MoHLV2FPT0WU
RPMI-6410 human leukemic lymphoblastoid cell lines Mo\mR5l1d3SxeHnjxsBie3OjeR?= MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBTWE2LLU[0NVAhcHWvYX6gcIV2c2WvaXOgcJlueGixYnzhd5RwcWRiY3XscEBtcW6nczygTWM2OD1yLkC2JO69VQ>? MWK2PFI4PTR4
human HT-29 cells MoXpVJJwdGmoZYLheIlwdiCjc4PhfS=> MmXCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDh[pRmeiB7NjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwME[2JO69VS5? MUWyO|c5PDR7
human NCI-H510A cell M1jCNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3HsUmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NVBCKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjhwMk[gcm0> NIPiU4xUSU6JRWK=
human J-RT3-T3-5 cell M1ThXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXfJcohq[mm2aX;uJI9nKGi3bXHuJGouWlR|LWSzMVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03QC52MjDuUS=> MYPTRW5ITVJ?
human VA-ES-BJ cell MoDhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlLHTY5pcWKrdHnvckBw\iCqdX3hckBXSS2HUz3CTkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcyNjZ3IH7N NYL0[IJFW0GQR1XS
human T-24 cell NV\IUII{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWrJcohq[mm2aX;uJI9nKGi3bXHuJHQuOjRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15OD61OkBvVQ>? M4DWdHNCVkeHUh?=
human NB69 cell NWXobJFzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV7QfldbUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|kvPDhibl2= M3nRVnNCVkeHUh?=
human BALL-1 cells MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4[0VFI1KGh? MoDpS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRmFNVC1zIHPlcIx{KGGodHXyJFI1KGi{czDifUBYW1RvMTDhd5NigSxiR1m1NF0xNjB6IN88US=> MVqyNlI3PDF5MB?=
HL60 cells M1LzfHBzd2yrZnXyZZRqd25iYYPzZZk> NVWwZWQyUW5idnn0do8hcW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgdJJwdGmoZYLheIlwdiCxZjDIUFYxKGOnbHzzMEBKSzVyPUCuNFgh|ryP Mmi3NVI5Pzd3OUO=
human CTV-1 cell NXHGWWF2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWnDfndwUW6qaXLpeIlwdiCxZjDoeY1idiCFVG[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg1Njd2IH7N M4XGN3NCVkeHUh?=
human MEL-JUSO cell Ml7wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHX1[HZKdmirYnn0bY9vKG:oIHj1cYFvKE2HTD3KWXNQKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QDVwN{[gcm0> MXjTRW5ITVJ?
human MOLT-4 cell M3yzSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXXJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUi5MlY4KG6P MVfTRW5ITVJ?
human leukemia cell line(CCRF-CEM) M3fZemN6fG:2b4jpZ:Kh[XO|YYm= NEnFOo5KdiC4aYTyc{BkgXSxdH;4bYNqfHlib3[gZ49ueG:3bnTzJJdmemViZHX0[ZJucW6nZDDvckBKdmirYnn0bY9vKG:oIHj1cYFvKGyndXvlcYliKGOnbHygcIlv\SiFQ2LGMWNGVSluIFnDOVA:OC5yOTFOwG0v NWTjN5RkQDlzN{[0OS=>
human SW982 cell Ml3NS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEPVfJZKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PVEvOjNibl2= NVLsfIhIW0GQR1XS
human NCI-SNU-1 cell NEnTdYZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWjUNFNiUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtV25WNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3Ojef-8kEBKSzVyPUm2Mlc4KG6P Mk\2V2FPT0WU
HeLa human cell lines NEXRS2RHfW6ldHnvckBie3OjeR?= MnrLNVQ1KGh? NGT1fYFVcGViY3;tdI92dmRid3HzJJRme3SnZDDpckB3cXS{bzDmc5Ih[W62aYT1cY9zKGGldHn2bZR6MDVyJTDpcohq[mm2aX;uJI9nKHS3bX;yJINmdGxiZ4Lve5RpMSCjZ3HpcpN1KEinTHGgbJVu[W5iY3XscEBtcW6nczDh[pRmeiBzNESgbJItKEmGNUC9NE4yKM7:TR?= NXrQZ3NvOzZ{NUexOC=>
human H460 cells M1PwZ2Z2dmO2aX;uJIF{e2G7 NUfOVXQyOjRiaB?= M4rIRWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi0OlAh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjedMg Ml;aNlAzOTF3NkS=
human HCT116 cells M1vjNGZ2dmO2aX;uJIF{e2G7 NH6wVnVCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlEh|ryP NF\IS28zODJzMUW2OC=>
human GP5d cell NV;TR2o2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYHJcohq[mm2aX;uJI9nKGi3bXHuJGdRPWRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMEKgcm0> NGDqTYtUSU6JRWK=
human SAS cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MULJcohq[mm2aX;uJI9nKGi3bXHuJHNCWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFyNz61O{BvVQ>? NHf0W2tUSU6JRWK=
human BFTC-905 cell  NYPBdndMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4SwWGlvcGmkaYTpc44hd2ZiaIXtZY4hSk[WQz25NFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yODhwM{Ggcm0> MWfTRW5ITVJ?
human LB1047-RCC cell NH\Ud|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NV23fm9OUW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUC4MlQzKG6P MnLYV2FPT0WU
human BB65-RCC cell M4O3U2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGJDPjVvUlPDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVExNjF7IH7N MnzpV2FPT0WU
human KE-37 cell NIryXlRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYjPfZZiUW6qaXLpeIlwdiCxZjDoeY1idiCNRT2zO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyOC56NTDuUS=> NXvkd2piW0GQR1XS
human NCI-H292 cell NHnjbodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVPCTmxzUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzND6yJI5O MmXMV2FPT0WU
human HT-1080 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2PUNGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyPC52NzDuUS=> NEfZNolUSU6JRWK=
human HL60 cells NF7mNmREgXSxdH;4bYPDqGG|c3H5 NX\HTFNnPDhiaB?= M2DRTGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlEyQCEQvF2= MVSxPVMzOTJ|NB?=
human CAKI-1 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4DVSWdzd3e2aDDpcohq[mm2aX;uJI9nKGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFI1KGi{czDifUBYW1RvMTDhd5NigSxiR1m1NF0xNjF{IN88US=> M1fpSFIzOjZ2MUew
human CAKI-1 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF3kR4tKdmirYnn0bY9vKG:oIHj1cYFvKEODS1mtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEzOCCwTR?= NEPKTFBUSU6JRWK=
human HMV-II cell M3;ocmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnvaTY5pcWKrdHnvckBw\iCqdX3hckBJVVZvSVmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfS=> NV;5VHlbW0GQR1XS
human ES8 cell NV3DV2d5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYXJcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF{Mz65N{BvVQ>? MVXTRW5ITVJ?
human NEC8 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHfmS4VKdmirYnn0bY9vKG:oIHj1cYFvKE6HQ{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN|QvOjFibl2= NH\JeXFUSU6JRWK=
human EW-1 cell M4\M[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zM{iuOlIhdk1? MmrQV2FPT0WU
murine leukemia P388 NWLnXId2TnWwY4Tpc44h[XO|YYm= NXzRNlQzSW62aXPhcoNmeiCjY4Tpeol1gSClYYLybYVlKG:3dDDpckB3cXS{bzDh[4FqdnO2IH31dolv\SCuZYXr[Y1q[SCSM{i4MEBKSzVyPUCuNVQh|ryP NX35SWx3OTF|NU[xNVA>
human H-EMC-SS cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmDYTY5pcWKrdHnvckBw\iCqdX3hckBJNUWPQz3TV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1PS5{ODDuUS=> MlrzV2FPT0WU
human SNU638 cells NHnpV4NEgXSxdH;4bYPDqGG|c3H5 M37YR2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNPXTZ|ODDj[YxteyCkeTDTVmIh[XO|YYmsJGlEPTB;MD6xOUDPxE1? MmPvNlQ6PTZ3NU[=
human COR-L105 cell M1Thfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXrJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYxNjN7IH7N NV\ZSIh5W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-mTOR / mTOR / p-S6K / S6K / p-AMPK / AMPK / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 24714637     


REH cells were incubated for the indicated time periods with cytarabine (3.2 μM) and the levels of phosphorylated/total mTOR, p70S6K, AMPK, Akt and ERK were determined by immunoblotting. The representative blots from three independent experiments are shown.

24714637
Growth inhibition assay
Cell viability; 

PubMed: 24714637     


REH cells were incubated in the presence of different concentrations of cytarabine and cell viability was determined by acid phosphatase assay after 24 h and 48 h. The data are mean ± SD values of triplicate measurements from a representative of three independent experiments (*p<0.05 compared to untreated cells). 

24714637
In vivo Cytarabine is highly effective against acute leukaemias, which causes the characteristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man. [4] Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity. [5]

Protocol

Kinase Assay:[1]
+ Expand

In Vitro Growth Inhibition Assay:

Stock solution of Cytarabine is prepared in absolute ethanol, and serial dilutions of Cytarabine are prepared. CCRF-CEM cells are suspended in RPMI medium supplemented with 10% FBS, 0.1% gentamicin, and 1% sodium pyruvate. The cells are suspended in their respective media to give 10 mL volumes of cell suspension at a final density of 3-6 × 104 cells/mL. Appropriate volumes of Cytarabine solution are transferred to the cell suspensions, and incubation is continued for 72 hours. The cells are spun down and resuspended in fresh Cytarabine -free medium, and final cell counts are determined. The data are analyzed by sigmoidal curve fitting of the cell count versus Cytarabine concentration, and the results are expressed as the IC50 (Cytarabine concentration that inhibits cell growth to 50% of the control value).
Cell Research:[2]
+ Expand
  • Cell lines: Rat leukemic cell lines RCL/0, RO/1 and K7 and human myelomonocytic leukemic U937
  • Concentrations: ~100 μM
  • Incubation Time: 24, 48 and 72 hours
  • Method: Cells are incubated in the presence of different concentrations of Cytarabine at 37 °C for 24, 48, and 72 hours. At the time of 20-, 44-, or 68-hour incubation in the presence of Cytarabine, 10 mL of cell proliferation reagent WST-1 solution is added. After 2- and 4-hour incubation with WST-1, cell metabolic activity is assessed with colorimetric changes quantified by measuring the absorbance in a spectrophotometer at 450 nm. And cell division times are calculated from eosin counting in parallel with viability assay
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Brown Norway rat with myelocytic leukaemia
  • Formulation: Dissolved in phosphate-buffered saline (pH 7.0) just before use.
  • Dosages: 5 - 1000 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro Water 48 mg/mL (197.35 mM)
DMSO 1 mg/mL (4.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 243.22
Formula

C9H13N3O5

CAS No. 147-94-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03878927 Recruiting Drug: CPX-351|Drug: Gemtuzumab Ozogamicin Acute Myeloid Leukemia Weill Medical College of Cornell University|Jazz Pharmaceuticals|Pfizer August 23 2019 Phase 1
NCT03896269 Recruiting Drug: Liposome-encapsulated Daunorubicin-Cytarabine Blasts 10-19 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|High Risk Chronic Myelomonocytic Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Chronic Myelomonocytic Leukemia|Refractory High Risk Myelodysplastic Syndrome M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 14 2019 Phase 1
NCT03348033 Enrolling by invitation Biological: Chronic Myeloid Leukemia + NK cell Chronic Myeloid Leukemia Hospital de Clinicas de Porto Alegre March 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Cytarabine | Cytarabine supplier | purchase Cytarabine | Cytarabine cost | Cytarabine manufacturer | order Cytarabine | Cytarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID